These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19904520)

  • 1. Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.
    Sumi M; Ichikawa N; Nasu K; Shimizu I; Ueki T; Ueno M; Kobayashi H
    Int J Hematol; 2009 Dec; 90(5):643-647. PubMed ID: 19904520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.
    Ando T; Mitani N; Matsunaga K; Nakazora T; Gondo T; Yujiri T; Tanizawa Y
    Tohoku J Exp Med; 2010 Feb; 220(2):121-6. PubMed ID: 20139663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
    Koren-Michowitz M; Maayan H; Apel A; Shem-Tov N; Yerushalmi R; Volchek Y; Avigdor A; Shimoni A; Nagler A
    Ann Hematol; 2015 Mar; 94(3):375-8. PubMed ID: 25307457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
    Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
    Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
    Wadleigh M; Richardson PG; Zahrieh D; Lee SJ; Cutler C; Ho V; Alyea EP; Antin JH; Stone RM; Soiffer RJ; DeAngelo DJ
    Blood; 2003 Sep; 102(5):1578-82. PubMed ID: 12738663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation.
    Chevallier P; Prebet T; Turlure P; Hunault M; Vigouroux S; Harousseau JL; Blaise D; Ifrah N; Milpied N; Mohty M
    Bone Marrow Transplant; 2010 Jan; 45(1):165-70. PubMed ID: 19584826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
    de Lima M; Champlin RE; Thall PF; Wang X; Martin TG; Cook JD; McCormick G; Qazilbash M; Kebriaei P; Couriel D; Shpall EJ; Khouri I; Anderlini P; Hosing C; Chan KW; Andersson BS; Patah PA; Caldera Z; Jabbour E; Giralt S
    Leukemia; 2008 Feb; 22(2):258-64. PubMed ID: 17989720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
    Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
    Leopold LH; Berger MS; Feingold J
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
    Zwaan CM; Reinhardt D; Corbacioglu S; van Wering ER; Bökkerink JP; Tissing WJ; Samuelsson U; Feingold J; Creutzig U; Kaspers GJ
    Blood; 2003 May; 101(10):3868-71. PubMed ID: 12543868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone.
    Tsunemine H; Akasaka H; Sakane EI; Ito K; Kodaka T; Takahashi T
    Int J Hematol; 2014 Feb; 99(2):193-7. PubMed ID: 24293280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia.
    Yamauchi T; Mori Y; Miyamoto T; Kamezaki K; Aoki T; Yamamoto A; Takenaka K; Iwasaki H; Harada N; Nagafuji K; Teshima T; Akashi K
    Int J Hematol; 2009 Oct; 90(3):416-420. PubMed ID: 19697098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
    Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
    Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
    Molnár I; Powell BL
    Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
    Debureaux PE; Labopin M; Mamez AC; Lapusan S; Isnard F; Adaeva R; Bonnin A; Hirsch P; Delhommeau F; Battipaglia G; Duléry R; Malard F; Vekhoff A; Mohty M; Legrand O; Brissot E
    Bone Marrow Transplant; 2020 Feb; 55(2):452-460. PubMed ID: 31554931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.